Clinical Trial Update: Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating daratumumab plus ibrutinib in Waldenström's macroglobulinemia; study status terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• daratumumab plus ibrutinib

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Waldenstrom Macroglobulinemia, Waldenstrom's Disease | Phase 2 | Status: TERMINATED | Results posted: 2023-10-23